 |
 |
 |
Teotten Technology
Teotten is developing diagnostics based on small molecule biomarkers present in the serum of
patients with infectious disease. This technology does not depend on the recovery of organisms
circulating in the blood. Since Teotten technology is based on circulating small molecules, it is
of particular utility for the detection of biofilm mediated infections, and of deep-tissue infections
such as those presenting as complications of cardiac surgery and joint replacement procedures.
Teotten’s first product in development utilizes a proprietary biosensor to detect a clinically
validated biomarker for invasive fungal disease. For Teotten’s next product lines, candidate
biomarkers for sepsis have been identified in a pre-clinical primate animal model system for
gram negative sepsis.
Diagnostics for life-threatening invasive fungal disease
Early detection and treatment is critical for patients at risk for invasive fungal disease. Using
current diagnostic technologies, the prognosis for patients identified with invasive fungal disease
remains at a sub-satisfactory level; there is a 50% chance of death from the disease. Patients at
risk for invasive fungal disease include those with malignancy, bone marrow or solid organ
transplant, neutropenia, other immuno-suppressive conditions, central venous catheters, and
patients in general in intensive care units. Although prophylactic antifungal drug treatment in at-
risk patients has been investigated, some antifungal drugs have undesirable toxicity. With only a
limited number of antifungal drug targets available, there is the risk for future failures in drug
therapy from the development of drug resistant pathogenic strains. The risk for drug resistance
has prompted clinicians to move away from prophylaxis and toward a targeted preemptive
strategy employing serial diagnostic testing and subsequent focused antifungal therapy.
Teotten is developing diagnostics based on small molecule biomarkers present in the serum of
patients with infectious disease. This technology does not depend on the recovery of organisms
circulating in the blood. Since Teotten technology is based on circulating small molecules, it is
of particular utility for the detection of biofilm mediated infections, and of deep-tissue infections
such as those presenting as complications of cardiac surgery and joint replacement procedures.
Teotten’s first product in development utilizes a proprietary biosensor to detect a clinically
validated biomarker for invasive fungal disease. For Teotten’s next product lines, candidate
biomarkers for sepsis have been identified in a pre-clinical primate animal model system for
gram negative sepsis.
Diagnostics for life-threatening invasive fungal disease
Early detection and treatment is critical for patients at risk for invasive fungal disease. Using
current diagnostic technologies, the prognosis for patients identified with invasive fungal disease
remains at a sub-satisfactory level; there is a 50% chance of death from the disease. Patients at
risk for invasive fungal disease include those with malignancy, bone marrow or solid organ
transplant, neutropenia, other immuno-suppressive conditions, central venous catheters, and
patients in general in intensive care units. Although prophylactic antifungal drug treatment in at-
risk patients has been investigated, some antifungal drugs have undesirable toxicity. With only a
limited number of antifungal drug targets available, there is the risk for future failures in drug
therapy from the development of drug resistant pathogenic strains. The risk for drug resistance
has prompted clinicians to move away from prophylaxis and toward a targeted preemptive
strategy employing serial diagnostic testing and subsequent focused antifungal therapy.
The graph below shows the reaction of Teotten's proprietary biosensor with a clinically
validated biomarker of invasive fungal disease.
validated biomarker of invasive fungal disease.
Diagnostics for life-threatening sepsis
Early detection and treatment is critical for patients at risk for sepsis. Currently, there are no
definitive diagnostic tests for this disease and, coupled with the fact that there is only a limited
number of drugs for treating sepsis, it is not surprising that the healthcare burden for this
disease is high. Using a pre-clinical animal model system, Teotten has identified candidate
biomarkers for sepsis. The graphs below show the identification of three candidate small
molecule biomarkers for sepsis.
Early detection and treatment is critical for patients at risk for sepsis. Currently, there are no
definitive diagnostic tests for this disease and, coupled with the fact that there is only a limited
number of drugs for treating sepsis, it is not surprising that the healthcare burden for this
disease is high. Using a pre-clinical animal model system, Teotten has identified candidate
biomarkers for sepsis. The graphs below show the identification of three candidate small
molecule biomarkers for sepsis.
| Technology |
